Trial: 201902074

A Phase 1/2 Study to Compare NKTR-214 Combined with Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI alone in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC)

Phase

I/II

Principal Investigator

Reimers, Melissa

Disease Site

Kidney

Learn more about this study at: clinicaltrials.gov